May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
BDNF Confers Long–Term Protection From the Retinal Toxicity of Verteporfin PDT
Author Affiliations & Notes
  • K.M. Donohue–Rolfe
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • D.M. Paskowitz
    UCSF School of Medicine, San Francisco, CA
    Medical Scientist Training Program,
  • H. Yang
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • K. Hosseini
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • C.M. Graybeal
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • G.C. Nune
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • D. Niculescu
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • M.A. Zarbin
    Institute of Ophthalmology and Visual Science, UMDNJ, Newark, NJ
  • M.M. LaVail
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • J.L. Duncan
    UCSF School of Medicine, San Francisco, CA
    Beckman Vision Center,
  • Footnotes
    Commercial Relationships  K.M. Donohue–Rolfe, None; D.M. Paskowitz, None; H. Yang, None; K. Hosseini, None; C.M. Graybeal, None; G.C. Nune, None; D. Niculescu, None; M.A. Zarbin, None; M.M. LaVail, None; J.L. Duncan, None.
  • Footnotes
    Support  Bernard A. Newcomb Fund, FFB, RPB, NIH Grants EY00415, EY01919, EY06842 and EY02162
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4819. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K.M. Donohue–Rolfe, D.M. Paskowitz, H. Yang, K. Hosseini, C.M. Graybeal, G.C. Nune, D. Niculescu, M.A. Zarbin, M.M. LaVail, J.L. Duncan; BDNF Confers Long–Term Protection From the Retinal Toxicity of Verteporfin PDT . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4819.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We showed previously that pretreatment with BDNF reduces the retinal toxicity observed 1 week after verteporfin photodynamic therapy (PDT) in a rat model. This study examines the rescue effect of BDNF 3 months after a single course of PDT, or after two PDT treatments 3 months apart. We also test the effect of CNTF, and a combination of BDNF and CNTF.

Methods: : For PDT, adult Brown–Norway rats received 6.0 mg/m2 verteporfin intravenously and 10 J/cm2 laser light at 689 nm delivered to the superior retina. Some animals received a second course of PDT, 3 months after the first. Two days prior to PDT, eyes were injected intravitreally with 2 µg BDNF, 2 µg CNTF, both factors, or PBS. Retinal function was evaluated using multifocal ERG, and structure was studied using light microscopy.

Results: : Three months after a single course of PDT, BDNF–treated eyes had 30% more surviving photoreceptors than PBS–treated eyes (p<0.005). Although mfERG responses were significantly better in the BDNF–treated eyes 1 week after PDT, visual function recovered in PBS–treated eyes so that there was no difference at 3 months. Three months after a second course of PDT, 3 of 5 animals showed dramatic rescue with 60% more surviving photoreceptors (p<0.035), but 2 animals with severe damage exhibited no rescue. Pretreatment with CNTF rescued photoreceptors 1 week after PDT in most animals, but significantly depressed mfERG responses. A combination of BDNF and CNTF produced significant rescue of photoreceptors 1 week after PDT, but depressed the mfERG.

Conclusions: : Protection by BDNF from the retinal toxicity of verteporfin PDT persists 3 months after treatment and is effective through more than one course of PDT in a majority of treated animals. Adjunctive therapy with BDNF has the potential to improve long–term visual outcomes in patients treated with PDT.

Keywords: photodynamic therapy • neuroprotection • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×